News
Chardan Capital Maintains Buy on Purple Biotech, Maintains $11 Price Target
7 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
5 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Purple Biotech Q4 EPS $(0.19), Inline
5 Mar 24
Earnings, News
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
27 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Purple Biotech Says Determined 100Mg/Kg Is The Recommended Phase 2 Dose For NT219 In Combination With Cetuximab In The Treatment Of Head And Neck Cancer Based On Its Phase 1/2 Dose Escalation Study
1 Feb 24
News
Press releases
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
14 Mar 24
Press Releases
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
5 Mar 24
Earnings, Press Releases
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
27 Feb 24
Press Releases
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
13 Feb 24
Press Releases
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
1 Feb 24
Health Care, Press Releases